- Home
- RGC vs RMD Comparison
RGC vs RMD Comparison
Compare RGC & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- RMD
- Stock Information
- Founded
- RGC 2014
- RMD 1989
- Country
- RGC Hong Kong
- RMD United States
- Employees
- RGC N/A
- RMD N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- RMD Medical/Dental Instruments
- Sector
- RGC Health Care
- RMD Health Care
- Exchange
- RGC Nasdaq
- RMD Nasdaq
- Market Cap
- RGC 38.6B
- RMD 36.7B
- IPO Year
- RGC 2021
- RMD 1995
- Fundamental
- Price
- RGC $14.66
- RMD $254.41
- Analyst Decision
- RGC
- RMD Buy
- Analyst Count
- RGC 0
- RMD 12
- Target Price
- RGC N/A
- RMD $259.40
- AVG Volume (30 Days)
- RGC 2.8M
- RMD 748.6K
- Earning Date
- RGC 06-30-2025
- RMD 07-31-2025
- Dividend Yield
- RGC N/A
- RMD 0.82%
- EPS Growth
- RGC N/A
- RMD 37.08
- EPS
- RGC N/A
- RMD 8.91
- Revenue
- RGC N/A
- RMD $5,021,529,000.00
- Revenue This Year
- RGC N/A
- RMD $10.37
- Revenue Next Year
- RGC N/A
- RMD $7.77
- P/E Ratio
- RGC N/A
- RMD $28.96
- Revenue Growth
- RGC N/A
- RMD 9.54
- 52 Week Low
- RGC $0.08
- RMD $195.00
- 52 Week High
- RGC $83.60
- RMD $263.05
- Technical
- Relative Strength Index (RSI)
- RGC 45.32
- RMD 52.85
- Support Level
- RGC $9.39
- RMD $251.40
- Resistance Level
- RGC $30.00
- RMD $261.08
- Average True Range (ATR)
- RGC 6.44
- RMD 4.21
- MACD
- RGC -1.70
- RMD -0.51
- Stochastic Oscillator
- RGC 20.68
- RMD 34.28
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About RMD ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.